<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44374">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02528617</url>
  </required_header>
  <id_info>
    <org_study_id>014-285</org_study_id>
    <nct_id>NCT02528617</nct_id>
  </id_info>
  <brief_title>The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease</brief_title>
  <official_title>The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Texas Scottish Rite Hospital for Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study the effect of Velaglucerase Alfa on skeletal bone
      development of children with Type 1 or Type 3 Gaucher Disease. In addition, the natural
      history and neurological status of children with Type 3 Gaucher Disease will be studied.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Z-scores from baseline in Skeletal Bone Mineral Density by Duel-energy X-ray absorptiometry (DXA) in children with Gaucher Disease type 1 and 3 receiving velaglucerase alfa.</measure>
    <time_frame>Baseline pre-intervention and yearly thereafter for 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in degrees/second from baseline in saccadic eye movements in children with Gaucher type 3 receiving velaglucerase alfa.</measure>
    <time_frame>Baseline pre intervention and yearly thereafter for 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline neurodevelopmental testing normalized scores in children with Gaucher Disease type 3 receiving velaglucerase alfa.</measure>
    <time_frame>Baseline pre intervention and yearly thereafter for 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline brainstem auditory evoked potential results measured in microvolts in children with Gaucher Disease type 3 receiving velaglucerase alfa.</measure>
    <time_frame>Baseline pre-intervention and yearly thereafter for 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline EEG (electroencephalogram) results measured in Hertz in children with Gaucher Disease type 3 receiving velaglucerase alfa.</measure>
    <time_frame>Baseline pre-intervention and yearly thereafter for 3 years.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Gaucher Disease Type 1</condition>
  <condition>Gaucher Disease Type 3</condition>
  <arm_group>
    <arm_group_label>Gaucher Type 1 or 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Velaglucerase alfa IV 60 units/kg every other week for duration of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velaglucerase alfa</intervention_name>
    <description>Enzyme replacement therapy</description>
    <arm_group_label>Gaucher Type 1 or 3</arm_group_label>
    <other_name>VPRIV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enzyme Replacement Therapy naive,

          -  confirmed diagnosis of Gaucher disease type 1 or 3,

          -  able to travel to Dallas, Texas 1x per year for baseline plus 3 consecutive years,

          -  able to tolerate all study procedures,

          -  skeleton not fully formed as confirmed by DXA and MRI),

          -  and willing to receive velaglucerase alfa infusions every other week for the duration
             of the study.

        Exclusion Criteria:

          -  Clinically unstable,

          -  taking or have taken bisphosphonates,

          -  Gaucher type 2,

          -  pregnant female,

          -  or deemed inappropriate for participation by the principal investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphael Schiffmann, M.D.,M.H.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor Research Institute/Institute of Metabolic Disease</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary E Wallace, MSRD/LD</last_name>
    <phone>214-820-4752</phone>
    <email>marywall@baylorhealth.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caren Swift, BSN</last_name>
    <phone>214-820-4857</phone>
    <email>caren.swift@baylorhealth.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary E Wallace, MSRD/LD</last_name>
      <phone>214-820-4752</phone>
      <email>marywall@baylorhealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Caren Swift, BSN</last_name>
      <phone>214-820-4857</phone>
      <email>caren.swift@baylorhealth.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 18, 2015</lastchanged_date>
  <firstreceived_date>July 28, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
